Identifying the determinants of adjuvant hormonal therapy medication taking behaviour in women with stages I-III breast cancer: A systematic review and meta-analysis by Cahir, Caitriona et al.
1 
 
Accepted refereed manuscript of:  
 
Cahir C, Guinan E, Dombrowski SU, Sharp L & Bennett K 
(2015) Identifying the determinants of adjuvant hormonal 
therapy medication taking behaviour in women with stages I-
III breast cancer: A systematic review and meta-
analysis, Patient Education and Counseling, 98 (12), pp. 1524-
1539. 
 
 
DOI: 10.1016/j.pec.2015.05.013 
© 2015, Elsevier. Licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International 
http://creativecommons.org/licenses/by-nc-nd/4.0/  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
Identifying the determinants of adjuvant hormonal therapy medication taking 
behaviour in women with stage I-III breast cancer: a systematic review and meta-
analysis  
 
Caitriona Cahir1, Emer Guinan2, Stephan U Dombrowski3, Linda Sharp4, Kathleen Bennett5 
Running head:  Adjuvant hormonal therapy medication taking behaviour 
Key words: Breast cancer, hormonal therapy, medication taking behaviour, Theoretical 
Domains Framework 
 
1 Department of Pharmacology & Therapeutics, Trinity College Dublin, Ireland and 
Economic and Social Research Institute, Dublin 2, Ireland   
2School of Physiotherapy, Trinity College Dublin, Ireland 
3Division of Psychology, University of Stirling, Scotland 
4 National Cancer Registry Ireland, Cork, Ireland 
5Department of Pharmacology & Therapeutics, Trinity College Dublin, Ireland 
 
Dr Caitriona Cahir (CC), Research Fellow 
Dr Emer Guinan (EG), Research Fellow 
Dr Stephan U Dombrowski (SD), Lecturer in Health Psychology; HCPC registered Health 
Psychologist  
Professor Linda Sharp (LS), Adjunct Professor in Epidemiology 
Dr Kathleen Bennett (KB), Associate Professor in Pharmacoepidemiology 
 
3 
 
Funding: CC is Health Research Board, Ireland (HRB) ICE fellow (ICE/2011/9)  
 
Correspondence to:  Dr Caitriona Cahir  
   Economic and Social Research Institute 
   Whitaker Square 
   Sir John Rogerson’s Quay 
   Dublin 2 
   Ireland 
   Ph: 00 353 1 8632000 
   Fax: 00 353 1 4539033 
   Email:  caitriona.cahir@esri.ie 
 
Competing interests: All authors have nothing to declare.  
 
Word Count: 3,997 
Total number of figures: 2 
Total number of tables: 4 
  
4 
 
Abstract (200 words) 
 
Objective 
This systematic review and meta-analysis aimed to identify the modifiable determinants of 
adjuvant hormonal therapy medication taking behaviour (MTB) in women with stage I-III 
breast cancer in clinical practice settings.  
Methods 
We searched PubMed, EMBASE, PsycINFO and CINAHL for articles investigating 
determinants of adjuvant hormonal therapy. Potentially modifiable determinants were 
identified and mapped to the 14 domains of the Theoretical Domains Framework (TDF), an 
integrative framework of theories of behavioural change. Meta-analysis was used to calculate 
pooled odds ratios for selected determinants. 
Results  
Potentially modifiable determinants were identified in 42 studies and mapped to 9 TDF 
domains. In meta-analysis treatment side-effects (Domain: Beliefs about Capabilities) and 
follow-up care with a general practitioner (vs. oncologist) (Social Influences) were 
significantly negatively associated with persistence (p<0.001) and number of medications 
(Behaviour Regulation) was significantly positively associated with persistence (p<0.003). 
Studies did not examine several domains (including Beliefs about Consequences, Intentions, 
Goals, Social Identity, Emotion and Knowledge) which have been reported to influence MTB 
in other disease groups. 
Conclusions 
5 
 
There is some evidence that the domains Beliefs about Capabilities, Behaviour Regulation 
and Social Influences influence hormonal therapy MTB.  
Practice Implications 
Further research is needed to develop effective interventions to improve hormonal therapy 
MTB. 
 
Highlights 
 This review identified modifiable determinants of hormonal therapy medication 
taking behaviour (MTB) 
 Modifiable determinants were mapped to the Theoretical Domains Framework  
 Beliefs about Capabilities,  Behaviour Regulation and Social Influences influence 
MTB 
 Several domains reported to influence MTB in other disease groups were not 
examined 
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1. Introduction 
Breast cancer survival in women has increased due to improvements in early diagnosis and 
the use of adjuvant hormonal therapy.(1) Five to ten years of adjuvant hormonal treatment 
has been shown to reduce the relative breast cancer recurrence risk by up to 50% in women 
with hormone responsive early breast cancer.(2, 3) Despite the proven clinical efficacy of 
adjuvant hormonal therapy many women do not take their treatment as prescribed. 
Medication taking behaviour (MTB) can be defined in terms of two distinct variables; 
persistence which is continuing the treatment for the prescribed duration of time and 
adherence which is acting in accordance with the prescribed interval and dosage of the 
treatment.(4) Non-persistence to hormonal therapy ranges from 13.6% at 1 year to 40.9% at 5 
years in routine clinical settings, while adherence ranges from 79.6% at 1 year to 68.3% at 5 
years.(5, 6) Non-persistence and non-adherence to hormonal therapy have been associated 
with increased risks of early breast cancer recurrence and death.(7, 8)  
 
MTB is influenced by a number of  factors, including socio-economic factors,  medical 
condition-related factors, therapy and treatment-related factors, health system-related factors 
and patient-related factors.(9) A systematic review published in 2012 reported that, despite 
the high prevalence of non-adherence and non-persistence with hormonal therapy, little is 
known about the factors associated with hormonal therapy MTB in women with breast 
cancer.(5) In particular, there is a critical need to identify potentially modifiable determinants 
that influence hormonal therapy MTB in order to develop behavioural interventions to 
improve it; no previous reviews have focussed on identifying the potentially modifiable 
determinants.(5) The aims of this systematic review were to; (i) identify the potentially 
modifiable determinants of adjuvant hormonal therapy MTB in women with stage I-III breast 
cancer in routine clinical practice settings and; (ii) to map these potentially modifiable 
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determinants to the Theoretical Domains Framework (TDF). The TDF is an integrative 
framework of multiple psychological theories of behaviour change designed to assess 
potential influences on individuals’ behaviours and inform intervention design.(10-12)  
The TDF has been applied in systematic reviews to identify the barriers and facilitators to 
behaviour change in clinical practice and develop theory-informed behaviour change 
interventions.(13-15) 
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2. Methods 
 
2.1. Eligibility, information sources and search strategies 
 
The study was conducted and reported in accordance with the Preferred Reporting of 
Systematic Reviews and Meta-Analysis (PRISMA) Statement guidelines.(16) An electronic 
database search of PubMed (via National Centre for Biotechnology Information), EMBASE 
(via Elsevier), PsycINFO (via EBSCO) and CINAHL (via EBSCO) was undertaken from 
database start to 31st March 2014 to identify studies that assessed determinants of adjuvant 
hormonal therapy MTB in women with stage I-III breast cancer in a clinical practice setting. 
Studies were considered eligible for review if they were; (i) published in a peer reviewed 
journal before 31st March 2014; (ii) reported data from a primary study (not a review, 
editorial or commentary); (iii) included female breast cancer patients who were prescribed 
adjuvant hormonal therapy; (iv) measured or assessed the determinants of adjuvant hormonal 
therapy MTB in clinical practice settings and; (v) were observational studies or randomised 
controlled trials (RCTs). Studies that examined adjuvant hormonal therapy MTB in women 
with ductal carcinoma in situ (DCIS) or in women with metastatic disease or exclusively after 
the initial 5 year period or after therapy switches or in clinical trials were excluded. 
MTB included persistence, adherence and initiation of adjuvant hormonal therapy. 
Persistence was defined as continuous use of adjuvant hormonal therapy, with few gaps in 
treatment or in prescription refills. Adherence was defined as the degree of conformity to the 
prescribed dosage and daily frequency of the treatment.(4) Initiation was defined as whether 
or not the patient commenced their adjuvant hormonal therapy the first time it was 
prescribed.(17) Persistence, adherence and initiation could be measured objectively or 
through self-report or self-assessment. Determinants included socio-economic factors (e.g. 
age, education), medical condition factors (e.g. tumour grade), therapy and treatment factors 
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(e.g. receipt of chemotherapy), health system factors (e.g. primary provider an oncologist) 
and patient factors (e.g. beliefs about treatment, doctor-patient communication). Adjuvant 
hormonal therapy included both selective estrogen-receptor modulators (e.g. tamoxifen) and 
aromatase inhibitors (e.g. letrozole). MeSH heading and text word searches were conducted 
as appropriate, with wildcards used to increase sensitivity. The search terms (non) complian*, 
(non) adherence, persist*, discontinu* were combined with various terms for hormonal 
therapy (e.g. antineoplastic agents, aromatase inhibitors, tamoxifen) according to the 
individual database requirements (Supplementary Table 1). The reference lists of eligible 
studies were scanned for additional studies.  
 
2.2. Study selection 
 
The titles and abstracts of all potentially eligible articles were reviewed independently by two 
reviewers (CC, EG) to determine their eligibility. Each reviewer coded the abstracts as; (i) 
eligible; (ii) possibly eligible or; (iii) not eligible. Abstracts considered eligible by both 
reviewers were included for further review. Abstracts identified as not eligible were 
excluded. Abstracts considered as possibly eligible by either reviewer, and those considered 
as eligible by one reviewer only, were discussed until consensus was reached (approximately 
3% of all abstracts were discussed).  
 
2.3. Data extraction 
 
The full text articles for abstracts identified as eligible were reviewed independently by the 
two reviewers (CC, EG). The following data were extracted from each: author, year of 
publication, country, participant characteristics, eligibility criteria, time period, type of 
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adjuvant hormonal therapy, measures of MTB and measures of determinants of adjuvant 
hormonal therapy MTB (Supplementary Table 2).  
 
2.4. Quality assessment 
 
The Downs and Black scale was used to critically assess and appraise all eligible studies in a 
standardised way, including the measurement of MTB, study methodology and statistical 
analysis. The scale includes questions about: (i) study quality; (ii) external validity; (iii) study 
bias; (iv) confounding and selection bias; and (v) power of the study.(18) The scale was 
modified to include items from the International Society of Pharamcoeconomics and 
Outcomes Research (ISPOR) checklist for studies of medication compliance and persistence 
that use administrative databases.(19) Each reviewer independently recorded the extent to 
which the studies adhered to the checklist and any methodological issues that emerged. 
 
2.5. Mapping determinants to the TDF 
 
The TDF was developed by Michie et al. in 2005 to simplify and integrate a number of 
behaviour change theories to provide a comprehensive assessment of behavioural 
determinants to inform systematic intervention design. These authors mapped 128 
explanatory constructs from 33 theories and identified 12 discrete domains of behaviour 
change synthesised into a single framework.(10, 12) The authors identified theories and 
theoretical constructs related to behaviour change and then grouped these constructs into 
overarching theoretical domains. Each domain is defined as ‘a group of related theoretical 
constructs’.(10) The TDF has recently been validated and refined to include 14 domains 
(Knowledge, Skills, Social and Professional Role and Identity, Beliefs about Capabilities, 
Optimism, Beliefs about Consequences, Reinforcement, Intention, Goals, Memory, Attention 
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and Decision Processes, Environmental Context and Resources, Social Influences, Emotion 
and Behaviour Regulation).(11) In this review, the modifiable determinants of adjuvant 
hormonal therapy MTB abstracted from the eligible papers were categorised into the 14 
domains by one reviewer (CC).(11) The categorisation process was independently reviewed 
by a second author (SD) with expertise in behavioural change theory. Categorisation was 
undertaken in a two-stage process. Firstly, if applicable the reported determinants were 
allocated to the domains suggested in the published frameworks.(10, 11) Secondly, some 
determinants were interpreted as proxy measures for a particular domain and allocated to that 
domain e.g. co-morbidities and number of medications were considered to be a proxy for 
behavioural regulation as managing a medication regime draws on an individuals’ regulatory 
capacity. Studies have shown that patients who are medication naïve have a higher risk of 
medication discontinuation.(20, 21) Similarly treatment side-effects was allocated to the 
domain Beliefs about Capabilities as patient expectations about their treatment, as well as 
coping skills and emotional representations of their illness have been found to predict the 
incidence of treatment side-effects in breast cancer.(22)   
 
Domains with more than two studies examining the association between a particular 
determinant and MTB, and where the studies were deemed sufficiently homogenous (e.g. 
similar in design, population, measure of MTB) for combination of results to be meaningful, 
were identified for potential meta-analysis. For these domains and their determinants, 
additional data extraction was undertaken independently by two reviewers (CC, KB); data 
was abstracted on statistical results of measures of association and also the details of any 
covariates adjusted for in the analysis. Authors of studies were contacted and asked to 
provide additional data or conduct further analysis where necessary.  
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2.6. Data synthesis  
 
Fixed and random effects models were used to calculate pooled odds ratios (ORs) for the 
association between the potentially modifiable determinants and the various measures of 
persistence, adherence and initiation. Tests for heterogeneity were conducted and the I2 
statistic was calculated to quantify the degree of heterogeneity between studies.(23) An I2 
value of 0% indicates no observed heterogeneity, values between 25%-50% indicate low 
heterogeneity and values between 50%-75% indicate moderate heterogeneity and values ≥ 
75% indicate high heterogeneity.(24) Overall estimates of the association between the 
determinants and MTB are presented in forest plots (Figure 2). All statistical analysis was 
performed using STATA 11.0 (Stata, College Station, TX). 
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3. Results 
 
3.1. Included studies 
Database searches identified 767 potentially eligible studies, of which 45 met the inclusion 
criteria (Figure 1).  In total 28 studies considered adherence to adjuvant hormonal therapy, 29 
studies considered persistence and 3 studies considered initiation.  Nineteen studies measured 
adherence to adjuvant hormonal therapy in administrative or prescription claims data or 
hospital/medical databases using a medication possession ratio (MPR) of ≥ 80%.(25-43) The 
MPR was generally calculated as the sum of the days supplied divided by the individual 
participant study period with a supply of 80% considered to be adherent.(44) Nine studies 
measured adherence using self-report measures.(34, 36, 45-51)  Two studies used a 
combination of both the MPR and self-report measures.(34, 36) Two studies measured 
adherence using a medication event monitoring system (MEMS).(52, 53)  Seventeen studies 
measured persistence using administrative or prescription claims data or hospital/medical 
databases. Persistence was generally defined as continuous use of adjuvant hormonal therapy 
with minimum treatment gaps ranging from 45 to 180 days.(26, 29-31, 33, 36, 38, 39, 42, 43, 
54-60) Eleven studies measured self-reported (non-)persistence (discontinuing treatment) (47, 
49, 61-69) and one study used medical chart review.(70) The three studies of initiation of 
hormonal therapy were based on self-report.(54, 66, 68) 
 
3.2. Quality assessment 
The majority of studies used standard methodology (e.g. MPR, treatment gaps, self-report) 
for measuring adherence, persistence and hormonal therapy initiation. No studies reported 
how anomalous values of MPR were accounted for in their analysis e.g. MPR > 100% or 
negative treatment gaps where patients may have been “hyper compliant/adherent” with their 
14 
 
treatment.(19) Studies differed in their choices of measures of determinants and covariates 
and some studies did not adjust for covariates in their analysis.(37, 46, 59) Some studies used 
selected patient groups (e.g. ≥70 years) and findings may not be generalisible to the general 
breast cancer population.(25, 42, 53) 
 
3.3. Mapping determinants to the TDF 
The determinants of hormonal therapy MTB studied included socio-demographic, diagnostic, 
clinical, treatment, health system and psychosocial factors (Supplementary Table 2). 
Potentially modifiable determinants were identified in 42 of the 45 studies; these mapped to 9 
of the possible 14 TDF domains (Table 1). No studies investigated determinants in the 
domains Skills, Optimism, Reinforcement, Intentions and Goals. Determinants were most 
frequently examined in the domains Social Influences (26 studies), Behaviour Regulation (25 
studies), Beliefs about Capabilities (13 studies), Emotion (11 studies) and Environmental 
Context and Resources (11 studies). Fewer studies investigated modifiable determinants 
within the domains Beliefs about Consequences (8 studies), Knowledge (5 studies), Memory, 
Attention and Decision Making (5 studies) and Social Identity (4 studies) (Table 1).  
The majority of the modifiable determinants within each domain had inconsistent or mixed 
associations with hormonal MTB (i.e. they were positively and negatively associated with 
MTB or unrelated) (Table 1). Only three determinants were identified for further 
investigation in meta-analysis; treatment side-effects (Beliefs about Capabilities), number of 
prescriptions- managing medication (Behaviour Regulation) and follow-up care- GP vs. 
oncologist (Social Influences). The studies concerning these three determinants were 
considered sufficiently homogenous for the combination of results to be meaningful.  
 
3.4. Beliefs about Capabilities- Treatment side-effects 
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Ten studies examined the association between treatment side-effects and hormonal therapy 
MTB (Table 2). Three studies reported a negative association between treatment side-effects 
and adherence to hormonal therapy (36, 45, 50) and four studies a negative association with 
persistence with hormonal therapy (61-63, 65, 67). Two studies reported no association 
between treatment side-effects and hormonal therapy adherence (34, 52) and one study no 
association with persistence.(64)  Data were pooled for meta-analysis from two adherence 
studies and two persistence studies (Figure 2).(36, 45, 63, 65) Women who reported side-
effects were significantly more likely not to persist with hormonal therapy (OR =5.73, 95% 
confidence intervals (CI) 3.87, 8.47, p<0.001). They were also less likely to adhere (OR= 
1.98, 95% CI 0.56, 0.71) but there was considerable heterogeneity (I2=78.6%) among the 
studies, with differences in study populations and follow up periods.(Figure 2) 
3.5. Behaviour regulation- Number of prescription medications 
Thirteen studies examined the association between number of prescription medications and 
hormonal therapy MTB.(Table 3) Six studies reported no association between number of 
medications and adherence to hormonal therapy (29, 33, 35, 37, 47, 50) and two studies no 
association with persistence.(33, 56) Seven studies reported a positive association between 
number of medications and persistence with hormonal therapy.(29, 42, 43, 60, 61, 64, 68) 
Data were pooled for meta-analysis from two adherence studies and two persistence studies 
(Figure 2).(33, 35, 61, 64) Women who were prescribed a greater number of medications 
were significantly more likely to persist with their hormonal therapy (OR=0.58, 95% CI 0.40, 
0.83, p<0.003). They were also less likely to be adherent (OR=0.98, 95% CI 0.96, 1.00) but 
there was substantial heterogeneity (I2=59.8%) among the studies, with differences in study 
time periods and types of hormonal therapy (Figure 2). 
3.6. Social Influences-Follow up care with general practitioner (GP) versus oncologist  
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Six studies examined the association between follow-up care and hormonal therapy MTB 
(Table 4). One study reported a negative association between follow-up care with a GP 
versus an oncologist and adherence to hormonal therapy (29) and five studies a negative 
association with persistence with hormonal therapy.(29, 39, 54, 58, 66) One study reported no 
association between follow-up care and adherence to hormonal therapy.(48) Data were 
pooled for meta-analysis from three studies which measured the association between follow-
up care and persistence with hormonal therapy (Figure 2).(29, 39, 54) Women whose follow-
up care was with their GP were significantly more likely not to persist with their hormonal 
therapy (OR=1.32, 95% CI 1.14, 1.54, p<0.001). 
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4. Discussion and Conclusion 
 
 
4.1. Discussion 
 
This systematic review is the first to examine potentially modifiable determinants of 
hormonal therapy MTB in women with breast cancer in routine clinical settings. Potentially 
modifiable determinants were identified in 42 studies and were classified into 9 domains 
from the TDF but most of these domains and their associated determinants were only 
examined in one or two studies. There is some evidence that the domains Beliefs about 
Capabilities (side-effects), Behaviour Regulation (managing medication) and Social 
Influences (follow-up care) influence adherence and persistence with hormonal therapy. As 
other previous reviews have noted, the majority of studies to date have examined 
sociodemographic, clinical or treatment related factors which cannot be modified and which 
are therefore, of little value in informing the development of interventions to enhance 
hormonal therapy MTB.(5, 71)   
Within the domain Beliefs about Capabilities treatment related side-effects were significantly 
associated with non-persistence in meta-analysis. Studies have shown that side-effects that 
affect quality of life in breast cancer patients are often not acknowledged or underestimated 
by clinicians.(72, 73) However studies have not identified whether it is the experience of 
side-effects per se or a lack of individual coping skills, self-efficacy, clinical support or 
coordination of care or a combination of these (or other) factors which lead to non-
persistence. There is also a lack of evidence on interventions to effectively manage hormonal 
therapy side-effects in breast cancer patients in clinical practice.(22) 
Medication beliefs have also been shown to influence patients’ actual experience of treatment 
side-effects and coping behaviours via negative expectancies, suggesting that interventions to 
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enhance MTB may need to include both Beliefs about Capabilities and Beliefs about 
Consequences.(74) Within the domain Beliefs about Consequences, lack of belief in the 
efficacy of hormonal therapy or lower perceived necessity was identified as potentially 
associated with hormonal therapy non-adherence and non-persistence.(46, 49, 51, 61, 64)  
However, the studies used various different measures of beliefs and some did not adjust for 
covariates.(46, 51, 68) The Health Beliefs Model (HBM) has been applied as a framework to 
explain MTB across disease groups, with beliefs about disease severity, personal 
susceptibility to recurrence, efficacy of treatment, self-efficacy, barriers to treatment and cues 
to action influencing health behaviours.(75, 76) The model has been extended to include the 
necessity-concerns framework where patients conduct a cost-benefit analysis by weighing up 
the necessity of their prescribed medication against concerns regarding potential adverse 
effects; this has been shown to influence adherence across disease groups.(76, 77)  Meta-
analyses has been conducted to test the power of the HBM to predict patient adherence and 
other health behaviours and has found that the relative importance of the components of the 
model (perceived susceptibility, severity, benefits, costs) vary between studies, but all 
components are related to better adherence.(76, 78) Patients’ beliefs about their breast cancer 
and the value of their hormonal therapy treatment (e.g. risk, benefits, treatment efficacy) and 
the  relationships of these beliefs  with hormonal therapy MTB have not yet been established 
using this model.  
In the domain Behaviour Regulation a greater number of medications was positively 
associated with persistence with hormonal therapy in meta-analysis. The number of 
medications was considered a proxy for medication management as studies have shown that 
patients who are medication naïve have a higher risk of medication discontinuation.(20, 21) 
Previous adherence has been reported to be the strongest predictor of future adherence 
suggesting that  identifying practical barriers to medication taking may improve adherence 
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and persistence.(79) Non-adherent women may benefit from the provision of aids (pill boxes) 
and action planning techniques e.g. set up of prompts or cues around the taking of hormonal 
therapy.(21) To date, few studies have investigated strategies for remembering to take 
hormonal therapy or the capacity to implement lifestyle modifications.(46, 50) Cognitive 
deficits also contribute to non-adherence, particularly in older breast cancer patients, 
suggesting that the domain Memory, attention and decision-making should be considered 
alongside the domain Behaviour Regulation.(80) There was mixed evidence that costs were 
associated with hormonal therapy MTB within the domain Environmental, Context and 
Resources (Table 1).  
The domain Social Influences identified follow up care with an oncologist (versus GP) to be 
associated with greater persistent with hormonal therapy in meta-analysis. Cancer patients 
who develop a strong alliance and trust in their oncologists have been shown to have greater 
psychosocial well-being and better treatment adherence.(81, 82) Studies of hormonal therapy 
MTB need to investigate the direct role that the physician-patient relationship has on 
treatment adherence and breast cancer outcomes. This could be through factors such as 
communication styles, time spent with patients or emotional and cognitive aspects of care. 
Good physician-patient communication has been found to be highly positively correlated 
with treatment adherence across diseases and training physicians to communicate better 
enhances patients’ adherence.(83)  Moreover, a linguistic study of oncologist-breast cancer 
patient communication reported that while discussions about hormonal therapy were 
generally good they often did not address potential difficulties of remaining adherent with 
long-term therapy.(84)  
Research is also needed on patient-physician collaboration and MTB; only three studies 
looked at patient participation in hormonal therapy decision making in the domain Social 
Identity.(43, 45, 63) A meta-analysis of 48 studies across chronic and acute conditions found 
20 
 
that greater physician-patient collaboration was significantly associated with better adherence 
and health outcomes.(85) Improvements in knowledge and understanding can  also be 
achieved through effective patient-physician collaboration and communication.(21) 
Educational materials have been reported not to improve adherence and persistence with 
hormonal therapy but it is possible that more “active” rather than passive delivery of 
information would be effective.  Studies on the amount and type of knowledge and patient 
understanding, as well as how this information is delivered are required within the domain 
Knowledge.(86, 87)  
Depression has been suggested to lead to negative attitudes towards breast cancer treatment 
plans and unwillingness to engage in treatment plans.(88) In the current review, the 
association was unclear between depression and hormonal therapy MTB (Table 1). Anxiety 
and distress about medical treatments have been shown to reduce adherence and uptake of 
healthy behaviours (e.g. clinical breast exams).(21, 89) A recent study has found therapy 
related negative emotions to be significantly related to hormonal therapy MTB and are 
potentially modifiable through psychological intervention.(90) The domain Emotion and the 
constructs within it also need to be investigated further alongside the domains Social 
Influences, Social Identity and Knowledge with healthcare providers addressing women’s 
apprehensions, uncertainty and reservations about hormonal therapy.  
Potential determinants within five of the TDF domains – Optimism, Skills, Intentions, Goals, 
and Reinforcement - were not investigated in any studies. There is some evidence that 
personality related factors such as resilience and self-determination within the domain 
Optimism influence ability to persist with medical treatment.(91) Previous meta-analysis has 
shown that intentions are one of the most influential determinants of actual behaviour and yet 
no studies have assessed the influence of the domains Intentions and Goals or Reinforcement 
on hormonal therapy MTB. Studies have shown patient self-regulation to be associated with 
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adherence to health-related behaviours with patients delaying short-term gratification in 
favour of long-term goals and overcoming numerous barriers and difficulties to achieve their 
long-term outcomes.(92) Non-adherence to medication has also been related to an inability to 
self-regulate with factors such as self-efficacy, attitudes and beliefs, perceived control, 
intentions, goal priority and action plans key determinants of MTB.(93, 94) Acceptability of 
hormonal therapy and motivation to persist with treatment may be influenced by women’s 
goal priorities or quality of life preferences. Studies are needed to explore determinants 
within these domains and establish their influence on hormonal therapy MTB.  
This review has identified potentially modifiable determinants of adjuvant hormonal therapy 
MTB in women with breast cancer using the TDF; however it has a number of limitations. 
There was considerable heterogeneity in studies included in the review, with various 
measures of MTB and its determinants considered. Only a small number of studies were 
included in the meta-analyses due to the lack of sufficiently homogenous studies and pooled 
estimates could be biased. Despite the small number of studies, the results of the meta-
analyses point to areas worthy of further exploration.(95)  The majority of studies in this 
review measured MTB using administrative or prescription claims data and prescription refill 
data does not establish whether the patient actually takes the medication or not. Studies were 
also predominantly based on European and American populations with healthcare access and 
findings may not apply to populations outside of Europe or America or minority or uninsured 
populations. This review did not include qualitative studies but only one such study using a 
mixed-methods approach was identified at the study selection process.(50)  
4.2. Conclusion 
As more and more patients survive breast cancer, hormonal therapy MTB becomes an 
increasingly important part of survivorship care in clinical practice.(1)  This is the first 
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systematic review to investigate potentially modifiable determinants of hormonal therapy 
MTB. This review has provided some evidence that the domains Beliefs about Capabilities, 
Behaviour Regulation and Social Influences influence adherence and persistence with 
hormonal therapy. However several other domains which have been reported to influence 
MTB in other disease groups – namely Beliefs about Consequences, Intentions, Goals, Social 
Identity, Emotion and Knowledge -have not been investigated in relation to hormonal therapy 
MTB in breast cancer.(21, 96) Moreover, the relationship between the various domains for 
MTB is unclear and needs to be tested in future studies.(15)  
4.3. Practice Implications 
The application of the TDF in this review permitted a comprehensive and systematic 
assessment of the evidence on potentially modifiable determinants that influence hormonal 
therapy MTB. The application of this theoretical framework has highlighted the critical need 
for further research in particular behavioural domains in order to inform the development of 
interventions. Fewer than half of published adherence-enhancing interventions have 
demonstrated improved MTB or enhanced patient outcomes; this is likely to be largely due to 
the fact that most interventions were developed without a thorough theoretical understanding 
of the factors that influence the behaviour of interest.(97, 98) A number of effective 
behaviour change techniques for behavioural interventions have been identified to target 
particular theoretical domains and these may form the basis for future evidence-based 
interventions.(99, 100) 
Hence, despite a relatively large evidence-base, the reasons why some women do not take 
their hormonal therapy as prescribed remain largely unclear. More concerted action is needed 
to identify potentially modifiable determinants of hormonal therapy MTB, to inform the 
development of effective interventions to promote adherence and persistence to hormonal 
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therapy; this would have considerable potential to improve clinical outcomes among women 
with breast cancer. 
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Table 1: Summary of studies reporting potentially modifiable determinants of 
hormonal therapy MTB mapped to the TDF 
TDF Domain TDF Construct Determinants  Adherence Persistence Initiation 
Knowledge  Knowledge of 
treatment  
Books/information leaflets about 
treatment 
 *  
  Inadequate information about 
treatment 
 - - 
  Discussion with physician about why 
treatment is needed 
*   
 Knowledge of 
side-effects 
Inadequate information on side-
effects  
 -  
Social Identity Patient role Perceived self-efficacy in patient-
physician interaction (low) 
-   
  Perceived less than adequate role in 
the decision making about treatment 
 - *  
  Decision making about treatment 
without adequate provider input 
 -  
  Multidimensional Health Locus of 
Control (weaker) 
-   
Beliefs about 
capabilities 
Coping with 
side-effects 
Treatment side-effects (general) ---  ** ----  *  
  Weight concern  -   
  Menopausal effects (hot flushes)  ++  
  Headaches  -  
  Loss of appetite  -  
  Nausea (vomiting)  -  
  Arthralgia (joint pain) - -  
Beliefs about 
consequences 
Beliefs about 
treatment 
Beliefs about treatment 
(benefit/drawback ratio) 
---  * ---  * * 
  Dislike taking medication -   
 Outcome 
expectancies 
Belief treatment will prevent breast 
cancer recurrence  
+   
Behaviour regulation Managing 
medication 
Number of co-morbidities ++  --  *** ++++  ---  
*********** 
* 
  Number of prescriptions (other 
medications) 
 ****** +++++++  ** * 
  Adding a new prescription (new 
medications) 
 --  
  Longer prescription refill intervals + +  
  Mail order pharmacy use +   
 Action planning Strategies employed to remember to 
take treatment (e.g. dosage box) 
+ *   
  Time of day treatment is taken *   
Memory, attention and 
decision making 
Memory Forgetting -   
  Figural memory (deficits) *   
  Verbal memory (deficits) -   
  Attention and working memory 
(deficits) 
-   *   
 Attention Cognitive function  *   
  Cognitive impairment  **  
Environmental context 
and resources 
Cost  Type of drug programme/insurance -   ** ****  
  Monthly cost of treatment   **  
  High out of pocket costs  -- --  
  Low material/financial support  *  
 Health system Problems receiving prescriptions 
from physician  
*   
Social Influences Personal support Married/relationship vs. single/other +++  -  **** 
 
+  --  ***  
  Receiving psychological support  **  
  Support of friends and relatives +   
  Insufficient social support   ---  
  Clinical support Pharmacy call back (follow up on 
hormonal therapy use) 
 *  
  Received psychological support since 
diagnosis  
 **  
  Follow up care- general practitioner 
(GP) vs. oncologist  
-   * ----- - 
  Referral/seeing medical oncologist  + ** + 
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TDF Domain TDF Construct Determinants  Adherence Persistence Initiation 
  One primary physician involved in 
follow up care 
 +  
  Increasing number of oncology visits 
during treatment  
-  * -  *  
  Frequency of physician 
communication (high/regular) 
++   
  Poor patient-physician 
communication 
- **  
  No opportunity to ask questions  -   *  
 Social norms Previous history of breast cancer *   
  History of cancer in family and/or 
social circle  
+  *** *  
Emotion Negative affect Depression --  * +  ***  
  Fatigue/inertia  *   
  Anxiety *   
  Psychological distress  --  
 Fear  Fear of breast cancer recurrence  + * + 
Determinants were examined in relation to adherence, non-adherence, persistence, non-persistence, initiation, non-initiation. A determinant 
positively associated with non-adherence was considered to be negatively associated with adherence.  
Each +, -, * represents one study. One study may include multiple determinants. 
+ Determinant positively associated with hormonal therapy adherence, persistence or initiation 
-  Determinant negatively associated with hormonal therapy adherence, persistence or initiation 
* Determinant has no association with hormonal therapy adherence, persistence or initiation
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Table 2:  Studies of treatment side-effects and adherence and persistence to adjuvant hormonal therapy among women with breast cancer in clinical practice settings (TDF 
domain Beliefs about Capabilities) 
Primary 
author, year 
Study type Country Participant 
characteristics  
Eligibility  criteria Time 
period 
 
HT Adherence  Persistence  Side-effects Results Covariates 
Liu, 2013 
(45) 
Prospective 
cohort  
US 303 women; 
mean age 51 
yrs; 49% less-
acculturated 
Latinas,  41% 
not completed 
high school 
Aged ≥18 years, 
newly diagnosed 
with BC, enrolled in 
the California 
Breast and Cervical 
Cancer Treatment 
Program (BCCTP)  
36 m TAM, AI Self-report  Not 
measured 
Abstracted 
from patient 
medical records 
(multiple side 
effects 
classified 
Yes/No) 
AOR = 0.26, 95% CI 0.11, 
0.63, p = 0.003 
Age, ethnicity, educational 
level, marital status, health 
insurance, financial 
adequacy, discussion with 
physicians about why 
hormonal therapy would 
be needed,  low patient-
doctor communication, 
low patient perceived self-
efficacy in patient-
physician interaction,  co-
morbidity, tumour stage, 
treatment received for BC- 
radiation therapy, 
chemotherapy, 
mastectomy 
Font, 2012 
(36) 
Cross-
sectional  
Spain 692 women;  
89% received 
chemotherapy 
and/or 
radiotherapy 
Diagnosis of BC 
stages I-IIIa, HR+, 
at least one rx for 
adjuvant endocrine 
treatment 
5 yrs TAM, AI Physician 
report, self-
report,  MPR 
≥ 80% drug 
reimbursement 
database 
≤  2 months 
between rx 
fills 
Abstracted 
from patient 
medical records 
(multiple side-
effects 
classified  
Yes/No) 
Physician adherence report 
AOR=1.81, 95% CI: 0.81, 
4.02 
 
Patient self-report  
AOR=1.06, 95% CI 0.49, 
2.28 
 
Prescription refill 
AOR=1.25, 95% CI 0.81, 
1.93 
Age, tumour stage, 
surgical treatment, type of 
surgical treatment 
(conservative breast 
surgery), radiotherapy, 
neoadjuvant 
chemotherapy, adjuvant 
chemotherapy, type of 
hormonal therapy  
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Primary 
author, year 
Study type Country Participant 
characteristics  
Eligibility  criteria Time 
period 
 
HT Adherence  Persistence  Side-effects Results Covariates 
Ziller, 2009 
(34) 
Retrospective 
cohort  
Germany 100 women; 
random sample 
taken (50 TAM 
and 50 AI) out 
of database of 
258 patients, 
mean age 65 
yrs (TAM), 71 
years (AI), 
Stage I-III BC 
Treated with 
surgery for BC at 
author clinic; 
assigned to adjuvant 
endocrine therapy; 
tx started 12-24 
months before 
interview; 
postmenopausal; 
Median 
time 13.6 
m (TAM), 
16.6 m 
(AI) 
TAM, AI MPR ≥ 80% ; 
self-report  
Not 
measured 
Abstracted 
from patient 
medical 
records:  
sweating, 
muscular 
problems, sleep 
disorders, 
anxiety, 
depression, 
exhaustion, 
sexual 
disorders, 
vaginal 
dryness, urinary 
tract problems 
Sweating               
OR=1.71, 95% CI: 0.36, 
8.15 
Muscular problems 
OR=0.64, 95% CI: 0.14, 
2.86 
Sleep disorders 
OR=0.34, 95% CI: 0.06, 
1.80 
Anxiety 
OR=0.38, 95% CI: 0.09, 
1.57 
Depression 
OR=1.22, 95% CI: 0.31, 
4.89 
Exhaustion 
OR=0.64, 95% CI: 0.14, 
2.86 
Sexual disorders 
OR=0.48, 95% CI: 0.12, 
1.96 
Vaginal dryness 
OR=1, 95% CI: 0.24, 4.11 
Urinary tract problems 
OR=1.15, 95% CI: 0.37, 
6.14 
No adjustment for 
covariates 
Wickersham, 
2013 (52) 
Prospective 
cohort  
US 198 women, 
mean age 59 
yrs, white 
(98.3%), 
educated  
(mean 15 yrs of 
schooling)  
Aged < 75 yrs, 
English speaking, 
minimum 8 years of 
education, oral HT 
alone or in 
combination with 
chemotherapy 
6 m TAM,AI Medication 
Event 
Monitoring 
System 
(MEMS)-  ≥ 
80% 
Not 
measured 
Breast Cancer 
Prevention 
Trial (BCPT) 
Symptom 
Checklist 
Correlation, r = 0.15 
between BCPT overall 
score and adherence (p ≤ 
0.20) 
 
Subscale weight concern 
scores (b=0.209 SE=0.039 
p = .003) in multiple 
regression model. No 
association reported for 
other subscales or BCPT 
overall score. 
Study membership, 
employment status, 
primary occupation 
(homemaker and related 
categories vs. other), DCIS 
tumour type, and 
menopausal status. 
Simon, 2014 
(50) 
Prospective 
cohort  
Canada 161women; 
mean age 56.6 
One clinic, ER+ BC 6 m TAM,AI Self-report- 
80% 
adherence, 
100% 
adherence 
Not 
measured 
Patient self-
report 
Qualitative analysis- side-
effects reported to be 
related to non-adherence 
(N=7) 
Not applicable 
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Primary 
author, year 
Study type Country Participant 
characteristics  
Eligibility  criteria Time 
period 
 
HT Adherence  Persistence  Side-effects Results Covariates 
Lash, 2006 
(61) 
Prospective 
cohort  
US 462 women; 
58%  aged 70-
79 yrs; 87% 
ER+ tumours 
Diagnosed with 
stage I-IIIA BC; age 
≥ 65 yrs; 
ER+/indeterminate 
tumours; initiated 
TAM 
63 m TAM Not measured Self-report 
continuing 
with 
treatment at 
each 
interview 3, 
6, 15, 27, 39, 
51, and 63 
months 
Patient self-
report: number 
of TAM side-
effects at 
baseline (≥1) 
and follow up 
3, 6, 15, 27, 39, 
51, and 63 
months 
Initial severe side effects: 
HR per side effect=1.2, 
95% CI 0.97, 1.5 
 
Developed new side-
effects: HR per new side 
effect=1.3, 95% CI 1.0, 
1.6. 
Age, enrolment site, 
estrogen receptor status, 
number of prescription 
medications taken,  
patients’ decisional 
balance scores 
 
Kahn, 2007 
(63)  
Cross-
sectional 
US 881; 85% 
white, one third 
≥ 65 yrs, 92% 
ER/PR+ 
tumour 
Diagnosed with 
stage I-III BC, 
registered by ACoS 
hospital  cancer 
registry; initiated 
TAM; age 21-80 yrs 
at dx 
4 yrs post 
dx 
TAM Not measured Self-report 
continuing 
with 
treatment (no 
time gaps 
specified) 
Patient self-
report - 
classified as 
severe, 
moderate, mild 
or none 
Severe side-effects 
AOR=5.95 95% CI 3.95, 
8.99 
Age, ethnicity, insurance, 
HR status, stage at 
diagnosis, lymph node 
involvement, BMI, 
comorbidity, surgery, 
chemotherapy,  radiation 
Demissie, 
2001(65) 
Prospective 
cohort 
US 303 women; 
mean age 67.7 
yrs, 50% 
married, 83% 
high school 
education 
Aged ≥ 55 yrs, 
newly diagnosed 
with stage I-III BC, 
no history of prior 
BC 
33 m TAM Not measured Self-report 
continuing 
with 
treatment at 
21 months 
Patient self-
report. Two 
dichotomous 
variables 
(Yes/No); hot 
flashes alone 
and any side 
effects, 
including hot 
flashes. 
Any side-effects  
AOR=4 95% CI 1.1-13.9 
Age, standard primary 
therapy, ER status , 
treatment decision making 
(sources of helpful 
information about BC and 
its treatment) 
Guth, 
2011(67) 
Retrospective 
cohort 
Switzerland 427 women, 
mean age 65.9 , 
majority stage 
I-II 
Diagnosed with 
non-metastatic BC, 
treated with surgery 
at author institution, 
ER/PR+ tumours, 
postmenopausal 
Median 
follow up 
16.5 m  
 
TAM, AI Not measured Self-report 
continuing 
with 
treatment 
Patient self-
report 
37 non-persistent and 24 
(64.9%) due to side-effects 
No adjustment for 
covariates 
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Primary 
author, year 
Study type Country Participant 
characteristics  
Eligibility  criteria Time 
period 
 
HT Adherence  Persistence  Side-effects Results Covariates 
Bowles, 2012 
(62) 
Cross-
sectional  
US 538, mean age 
64 yrs; 90% 
white; 
postmenopausal 
Diagnosed with BC, 
received at least one 
TAM, AI rx within 
12 m after dx, 
postmenopausal 
3 m TAM, AI Not measured Self-report 
continuing 
with 
treatment for 
5 yrs. 
Validated 
against 
pharmacy 
data. 
Patient self-
report 
Headaches:  
AIs: AOR = 4.16; 95% CI, 
2.16, 8.01  
TAM: AOR =2.34; 95% 
CI, 1.24, 4.41.  
 
Loss of appetite, upset 
stomach, or vomiting  
TAM: AOR 2.45; 95% CI, 
1.14, 5.28.  
 
Hormone or menopause-
related adverse effects  
AIs: AOR 0.35; 95% 
CI,0.18, 0.70 
TAM: AOR 0.45, 95% CI, 
0.24, 0.83. 
 
Age, year of diagnosis 
Fink, 2004 
(64) 
Prospective 
cohort 
US 516; majority 
aged  ≥ 70 yrs, 
high school 
graduates 
Diagnosed with 
stage I-IIIA BC, no 
prior history of BC; 
age ≥ 65 yrs; ER+ 
tumours; prescribed 
and taking TAM 
27 m TAM Not measured Self-report 
continuing 
with 
treatment at 
each 
interview. 
Subset 
validated 
against 
pharmacy 
records 
Items from the 
National 
Surgical 
Adjuvant 
Breast and 
Bowel Project 
Breast Cancer 
Prevention 
Trial13. 
Classified the 
number of 
reported severe 
side effects as 
0, 1, or 2. 
1 side-effect: OR=1.3 95% 
CI 0.72, 2.3  
  
≥2 side-effects: OR=1.1 
95% CI 0.64, 1.9  
 
Recalculated as any side-
effects: OR= 1.23 95% CI 
0.74, 1.87 
No adjustment for 
covariates 
BC breast cancer, m months, yrs years, AI aromatase inhibitor, TAM tamoxifen, MPR medication possession ratio, tx treatment, rx prescription, dx diagnosis, ER/PR+ estrogen or progesterone receptor positive, AOR adjusted odds ratios, 
OR odds ratio, HR hazard ratio, CI confidence intervals
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Table 3:  Number of medications and adherence and persistence to adjuvant hormonal therapy among women with breast cancer in clinical practice settings (TDF domain 
Behaviour Regulation) 
Primary 
author, year 
Study type Country Participant 
characteristics 
Eligibility criteria Time 
period 
HT Adherence Persistence Number of 
medications 
Results Covariates 
Neugut, 
2011(29) 
Retrospective 
cohort 
US 22,160 (8,110 <65 
yrs, 14,050 ≥ 65 
yrs)/mean age 67.4 
yrs, 
postmenopausal: 
89.5% white, 74.3% 
married 
Diagnosed with 
early stage BC; 
filled at least two 90 
day mail order rx for 
an AI bwt 2007 - 
2008: age ≥ 50 yrs 
2 yrs AI MPR ≥ 80% Minimum 45 days 
elapsed from prior 
rx without a refill, 
with no 
subsequent refills 
before end of 
study period 
Total number 
of 
prescriptions 
filled or 
refilled for 
each patient 
within the 
prior 12 
months 
 
 
< 65 years non-adherence: 
5-9 meds vs < 5: 
AOR= 0.93 95% CI 0.76, 
1.14 
10-14 meds vs < 5: AOR= 
0.86 95% CI 0.70, 1.07 
≥ 15 meds vs < 5; 
AOR=0.85 95% CI 0.68, 
1.07 
 
≥ 65 years non-adherence: 
5-9 meds vs < 5: 
AOR= 1.10 95% CI 0.90, 
1.34 
10-14 meds vs < 5: AOR= 
1.04 95% CI 0.85, 1.28 
≥ 15 meds vs < 5; 
AOR=0.85 95% CI 0.70, 
1.04 
 
< 65 years non-
persistence: 
5-9 meds vs < 5: 
AOR= 0.92 95% CI 0.79, 
1.07 
10-14 meds vs < 5: AOR= 
0.75 95% CI 0.64, 0.89 
≥ 15 meds vs < 5; 
AOR=0.57 95% CI 0.48, 
0.67 
 
≥ 65 years non-
persistence: 
5-9 meds vs < 5: 
AOR= 0.84 95% CI 0.73, 
0.96 
10-14 meds vs < 5: AOR= 
0.74 95% CI 0.64, 0.85 
≥ 15 meds vs < 5; 
AOR=0.60 95% CI 0.52, 
0.68 
 
Age, race, marital 
status, income, 
region, 90 day out of 
pocket cost, follow 
up with primary care 
physician vs 
oncologist, 
comorbidities 
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Primary 
author, year 
Study type Country Participant 
characteristics 
Eligibility criteria Time 
period 
HT Adherence Persistence Number of 
medications 
Results Covariates 
Kimmick, 2009 
(33) 
Retrospective 
cohort 
 
  
US 1,491; mean age 67 
yrs (range 29-102), 
59% White, low 
income, insured via 
gov programmes, 
60% ER/PR+ 
tumours 
Non-metastatic 
invasive BC 1998-
2002, HR+ or 
unknown BCs, 
continuously 
enrolled in Medicaid 
for the 24 months 
after dx, local or 
regional staging, 
breast-conserving 
surgery or 
mastectomy, non-
missing data on 
radiation status 
1 yr TAM, AI MPR ≥ 80% No more than 90 
days between rx 
fills or in tx gaps 
Number of 
unique 
prescription 
meds within 
12 months  
Adherence: AOR=1.01 
95% CI 0.99, 1.02 per unit 
increase in meds  
 
Persistence: AOR=1.06 
95% CI 1.05, 1.08 per unit 
increase in meds 
Age, race, 
comorbidity, marital 
status, stage, HR 
status, type of 
surgery, 
chemotherapy, 
radiation, urban 
residence, type of 
hospital 
Krotneva, 2014 
(42) 
Prospective 
cohort study 
Canada 3180; mean age 77 
yrs 
ER+, ≥ 1 year of 
medical service 
history, initiated  HT 
within 1 year of 
BCS 
5 yrs TAM, AI MPR ≥ 80% No more than 60 
days between rx 
fills or in tx gaps 
Number of 
prescription 
medications 
at baseline 
Non-persistence: HR= 0.93 
95% CI 0.92, 0.95 per unit 
increase in number of 
prescription items 
Age, are of residence, 
comorbidity, new 
medication initiated, 
radiotherapy, hospital 
admissions 
Markkula, 2012 
(37) 
Prospective 
cohort 
Sweden  417; median age 60 
yrs, range 25-99 
Patients ≥1 yr of 
follow up, had not 
received 
neoadjuvant 
treatment, advised to 
use HT, ER+, not 
been treated for 
another type of 
cancer in the 
previous 10 years 
2 yrs TAM,AI Declined 
treatment, 
MPR>80% 
from medical 
chart, patient 
questionnaire 
Stopped treatment 
upon follow up 
from medical 
chart, patient 
questionnaire 
Number of 
medicines for 
comorbidities  
from 
questionnaire 
excluding 
complementar
y taken in the 
last week 
Adherence and 
persistence:  
≥2 v <2 at 1y: OR=1.01, 
95% CI 0.54, 1.89 
≥2 v <2 at 2y: OR=0.84, 
95% CI 0.12, 1.63 
No adjustment 
Partridge, 2003 
(35) 
Retrospective 
cohort 
US 2,378; mean age 
75.4 yrs; 83% 
White; 63% locally 
staged disease 
Continuously 
enrolled in state 
Medicaid prgm 
during study period; 
age ≥ 18 yrs; fill at 
least one TAM rx; 
history of definitive 
BC surgery 
1-4 yr TAM MPR ≥ 80%, 
proportion of 
days before 
any evidence 
of recurrence 
or new BC or 
any TAM 
adverse event  
Not measure Number of 
other 
prescription 
drugs used 
AOR= 1.03, 95% CI 1.0, 
1.04 per item increase 
Age, race, surgery, 
oncology provider, 
Charlson score, 
outpatient services, 
days hospitalised 
Atkins, 2006 
(47) 
Cross-
sectional -
Semi-
structured 
interviews 
UK 131;mean age 59.4, 
63% married, 53% 
at least secondary 
level education 
2 yrs post dx, stable 
disease, English 
speaking 
2 yrs TAM, AI Self-report: 
Forgetting to 
take 
medication 
(non-
intentional 
adherence) 
and choosing 
not to take 
medication 
(intentional 
adherence) 
Not measured Number of 
other 
prescription 
drugs used 
No association  No adjustment 
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Primary 
author, year 
Study type Country Participant 
characteristics 
Eligibility criteria Time 
period 
HT Adherence Persistence Number of 
medications 
Results Covariates 
Simon, 
2014(50) 
Cross-
sectional 
Canada 161; mean age 56.6 
yrs 
One clinic, treated 
for ER+ BC 
6 m TAM, AI Self-report 
interview, 
80% 
adherence 
intake, 100% 
adherence 
intake 
Not measured Chronic 
medication 
for 
comorbidities  
80% adherence: 0.001 
(0.00, 100.00) 
 
100% adherence: 0.28 
(0.03, 2.43) 
Age, menopause 
status, HT, 
chemotherapy, 
tumour status, node 
status, mastectomy, 
HRT, history of BC 
Huiart , 
2013(43) 
Prospective 
cohort 
France 382 women, mean 
age 71.8 yrs 
≥ 1 rx for AI Median 
period 
3.2 yrs 
AI MPR ≥ 80% First tx 
discontinuation 
lasting more than 
3 consecutive 
months 
Polypharmac
y (> 4 meds) 
(Yes or No) 
Non-persistence: HR= 
0.40, 95% CI 0.18, 0.88  
Complementary/Alter
native therapy, 
comorbidities  
Lash, 2006 (61) Prospective 
cohort  
US 462; 58%  aged 70-
79 yrs; 87% ER+ 
tumours 
Diagnosed with 
stage I-IIIA BC; age 
≥ 65 yrs; 
ER+/indeterminate 
tumours; initiated 
TAM 
63 m TAM Not measured Self-report 
continuing with 
treatment at each 
interview 3, 6, 15, 
27, 39, 51, and 63 
months 
Number of 
prescription 
medications 
at baseline 
3 meds vs ≤ 2: 
RR=0.79 95% CI 0.48, 1.3 
4 meds vs ≤ 2: RR=0.59, 
95% CI 0.33, 1.1 
≥ 5 meds vs ≤ 2: 
RR= 0.62, 95% CI 0.40, 
0.96 
 
ARR= 1.20 95% CI 1.0, 
1.4 per additional 
prescription 
 
Age, enrolment site 
ER status, presence 
of severe TAM side 
effects, patients’ 
decisional balance 
scale 
Fink, 2004 (64) Prospective 
cohort 
US 516; majority aged  
≥ 70 yrs, high 
school graduates 
Diagnosed with 
stage I-IIIA BC, no 
prior history of BC; 
age ≥ 65 yrs; ER+ 
tumours; prescribed 
and taking TAM 
27 m TAM Not measured Self-report 
continuing with 
treatment at each 
interview. Subset 
validated against 
pharmacy records 
Number of 
prescription 
medications, 
including 
TAM 
classified as 0 
to 2, 3, 4, and 
≥5  
3 meds vs ≤ 2: 
RR=0.66 95% CI 0.34, 1.2 
4 meds vs ≤ 2: RR=0.47, 
95% CI 0.25, 0.88 
≥ 5 meds vs ≤ 2: 
RR= 0.49, 95% CI 0.27, 
0.98 
 
No adjustment 
Friese, 2013 
(68) 
Prospective 
cohort  
US 743; mean age 58.9 
yrs 
Age 20-79 yrs, 
Stages I-III BC, 
ER+ or PR+ 
4 yrs TAM, AI Not measured Self-report 
continuing with 
treatment 
Number of 
medications 
taken in the 
week prior to 
the follow up 
survey (4 
years since 
dx)  classified 
as 0,1 and ≥2  
≥2 vs 0 to 1:  
AOR=4.19 95% CI 2.28, 
7.68 
Age, race, SEER 
stage, SEER grade, 
worry about 
recurrence, primary 
oncology provider 
Van Herk-
Sukel, 
2010(56) 
Retrospective 
cohort 
Netherlands 1,725; 1,451 TAM BC Stage I-IIIa,  HT 
within 1 yr dx, time 
period 1998-2006 
5 yrs TAM, AI Not measured No more than 60 
days between rx 
fills or in tx gaps, 
also looked at < 
90 days and < 180 
days 
Number of 
different drug 
classes (ATC 
level 1) 
2-3 vs <2: AOR=0.82 95% 
CI 0.62, 1.07 
4-5 vs <2: AOR=0.89 95% 
CI 0.68, 1.17 
6+ vs <2: AOR=1.15 95% 
CI 0.89, 1.49 
Age, tumour size, 
number of 
comorbidities  
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Primary 
author, year 
Study type Country Participant 
characteristics 
Eligibility criteria Time 
period 
HT Adherence Persistence Number of 
medications 
Results Covariates 
Barron, 
2007(60) 
Retrospective 
cohort 
Ireland 2,816; one-third 
aged ≥ 75 
Aged ≥ 35 yrs, 
commenced TAM as 
initial HT between 
Jan 2001- Jan 2004 
1- 3.5 
yrs 
(media
n 2.7 
yrs) 
TAM Not measured No more than 180 
days between rx 
fills after index 
date, excluded 
treatment 
switchers, those 
lost to follow up 
(no prescription 
for any item) 
Mean number 
of 
pharmacologi
cal agents in 
year before 
Tam 
1-3 vs <=1: AOR= 0.84, 
95% CI 0.71, 1.00 
>3-5 vs <=1: AOR=0.76, 
95% CI 0.61, 0.94 
>5 vs <=1: AOR=0.72, 
95% CI 0.58, 0.92 
Age, antidepressant 
use, number of 
cognitive or 
functional 
impairments 
BC breast cancer, m months, yrs years, AI aromatase inhibitor, TAM tamoxifen, MPR medication possession ratio, tx treatment, rx prescription, dx diagnosis, ER/PR+ estrogen or progesterone receptor positive, AOR adjusted odds ratios, 
OR odds ratio, HR hazard ratio, CI confidence intervals
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Table 4:  Follow up with GP vs oncologist and adherence and persistence to adjuvant hormonal therapy among women with breast cancer in clinical practice settings (TDF 
domain Social Influences) 
Primary 
author, year 
Study type Country Participant 
characteristics 
Eligibility criteria Time 
period 
HT Adherence Persistence Follow up Results Covariates 
Neugut, 
2011(29) 
Retrospective 
cohort 
US 22,160 (8,110 <65 yrs, 
14,050 ≥ 65 yrs)/mean 
age 67.4 yrs, 
postmenopausal: 
89.5% white, 74.3% 
married 
Diagnosed with early 
stage BC; filled at 
least two 90 day mail 
order rx for an AI 
bwt 2007 - 2008: age 
≥ 50 yrs 
2 yrs AI MPR ≥ 80% Minimum 45 
days elapsed 
from prior rx 
without a refill, 
with no 
subsequent 
refills before 
end of study 
period 
Follow up 
with 
primary 
care 
physician 
vs. 
oncologist  
< 65 yrs: AOR=0.91 
95% CI 0.71,1.16 
(adherence) 
> 65 yrs: AOR= 0.81 
95% CI 0.69, 0.96 
(adherence) 
65 yrs: AOR=0.82 
95% CI 0.69,0.99 
(persistence) 
> 65 yrs: AOR= 0.79 
95% CI 0.71, 0.89 
(persistence) 
Age, race, marital 
status, income, 
region, 90 day out 
of pocket cost, no 
of other 
prescriptions, 
comorbidities 
 
 
Danilak, 2013 
(39) 
Retrospective 
cohort  
Canada 346;  majority aged 35-
74 yrs 
Initiated adjuvant 
endocrine therapy, 
HR+, node positive 
or intermediate to 
high-risk node 
negative patients, 
completed primary 
surgery and 
chemotherapy. 
2 yrs TAM, AI After ≥2 yrs; 
MPR ≥ 80% 
Discontinued 
therapy within 3 
m, 6 m, 1 yr and 
2 yrs 
Cross 
Cancer 
Institute 
follow-up 
times of 
less than 1 
yr 
(discharged 
to family 
physician)  
AOR= 2.4  95% CI 
1.0, 5.5   (non-
persistence) 
Age, residence 
(near centre), 
Chemotherapy,  
menopausal status, 
nodal status, 
surgery, radiation, 
pharmacy call back 
Alkhayyat, 
2012 (48) 
Case-control Canada 160; (80 in each 
cohort), median age 
62.5 yrs 
ER+, therapy ≥ 1 yr 5 yrs TAM, AI Adherent 
>80%, non-
adherent < 
50%, semi-
adherent 50-
80% 
Not measured Follow up 
with 
primary 
care 
physician 
vs. 
oncologist 
HR= 0.7 (p > 0.999) No adjustment 
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Primary 
author, year 
Study type Country Participant 
characteristics 
Eligibility criteria Time 
period 
HT Adherence Persistence Follow up Results Covariates 
Güth, 2008 
(66) 
Retrospective 
hospital based 
cohort 
Switzerland 325; mean age 67.3  
yrs (range 47-95); 
majority stage I-IIA 
Diagnosed with non-
metastatic BC, 
treated with surgery 
at author institution, 
ER/PR+ tumours, 
postmenopausal 
5 yrs TAM, AI Not measured Patients who 
discontinued per 
medical record 
Follow up 
with 
primary 
care 
physician 
vs. 
oncologist  
OR= 2.78 95% CI 
1.29, 5.98  
No adjustment 
Güth, 2012 
(54) 
Retrospective 
hospital based 
cohort  
Switzerland 685; mean age 60 yrs,  
diagnosed with ER+ 
BC 1997-2008 at a 
university teaching 
hospital 
HR+ non-metastatic 
invasive BC, 
received surgical 
therapy between 
1997-2008.  
Minimum 
36 m 
TAM, AI Not measured Persistence- 
discontinue 
treatment except 
for BC 
recurrence, 
physician 
decided to stop 
treatment, 
patients who 
died per medical 
record 
Follow up 
with 
primary 
care 
physician 
vs. 
oncologist  
AOR= 0.66 95% CI 
0.49, 0.88 
Year of the initial 
diagnosis, patient’s 
age at diagnosis, 
primary surgical 
therapy, tumor 
stage, receipt of 
previous 
chemotherapy 
and/or 
postoperative 
radiation 
 
Hadji, 2013 
(58) 
Cross-sectional Germany 12,412; mean age 62 
yrs TAM, 66 yrs AI 
BC, first rx for 
TAM, AI Oct 2001-
Dec 2010 (follow up 
time ≥365 days 
before index date), 
≥18 years 
3m to 3 yrs 
from index 
date 
TAM, AI Not measured 90 days without 
hormonal 
therapy 
Follow up 
with 
primary 
care 
physician 
vs. 
oncologist 
HR=0.44  95% CI 
0.42, 0.46 
Age, type of health 
insurance, patient 
and physicians 
residency, baseline 
co-morbidities 
(osteoporosis, 
diabetes, 
depression) and co-
medication 
(bisphosphonates 
for osteoporosis) 
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Figure 1: PRISMA Flow Diagram: selection of studies for systematic review 
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                                                                                                           Non-persistence (treatment gaps) and follow up with GP vs oncologist 
 
                                                                     
 Figure 2: Forest plots: Side-effects, number of medications and follow up with GP vs. oncologist and non-adherence and non-
persistence to adjuvant hormonal therapy  
 
Notes: Non-adherence and side-effects: Populations different- Liu 2013 study predominantly low education and low income. Different time periods, Liu 2013 study was 36 m vs. 5 yrs for Font 2012 study.                       
Non-persistence and side-effects: Different time periods, Kahn 2007 study was 4 yrs vs. 21 m for Demissie 2001 study. Kahn 2007study analysed severe side-effects only. Including Fink 2004 study and Bowles 2012 
study:  Heterogeneity chi-squared = 25.87 (d.f. = 3) p = 0.000,  I2= 88.4%. Test of ES=1 : z= 7.65 p = 0.000.Fink 2004 study did not adjust for any covariates and Bowles 2012 study measured specific side-effects 
(hormone, bone related) 
Non-adherence and number of medications: Both studies measured per unit increase in number of medications. Kimmick 2009 study was 1 yr vs 1 to 4 yrs Partridge 2009 study. Kimmick 2009 study measured 
adherence to TAM, AI. Partridge 2009 measured adherence to TAM only.  
Non-persistence and number of medications: Both studies measured ≥ 5 medications versus ≤ 2 medications. No adjustment for covariates.  
Non-persistence and follow-up with GP vs oncologist: Neugut 2011 study included women < 65 years only as similar to mean age in Danilak 2013 and Guth 2012 studies 
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